NCT05283135 - High Dose Risankizumab for Psoriasis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 1, 2022

Primary Completion Date

August 7, 2023

Study Completion Date

July 10, 2024

Conditions

Psoriasis

Interventions

DRUG

risankizumab

Risankizumab (Skyrizi) is an anti-IL-23 antibody being investigated for the treatment of multiple inflammatory diseases, including psoriasis, Crohn's disease, ulcerative colitis, and psoriatic arthritis.

Trial Locations (1)

97201

Oregon Medical Research Center, Portland